207 related articles for article (PubMed ID: 31359769)
1. Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center.
Moonla C; Akkawat B; Kittikalayawong Y; Sukperm A; Meesanun M; Uaprasert N; Sosothikul D; Rojnuckarin P
Clin Appl Thromb Hemost; 2019; 25():1076029619866916. PubMed ID: 31359769
[TBL] [Abstract][Full Text] [Related]
2. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
[TBL] [Abstract][Full Text] [Related]
3. Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow-chamber system.
Nogami K; Ogiwara K; Yada K; Shida Y; Takeyama M; Yaoi H; Minami H; Furukawa S; Hosokawa K; Shima M
J Thromb Haemost; 2016 Apr; 14(4):667-74. PubMed ID: 27061057
[TBL] [Abstract][Full Text] [Related]
4. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.
Sanders YV; van der Bom JG; Isaacs A; Cnossen MH; de Maat MP; Laros-van Gorkom BA; Fijnvandraat K; Meijer K; van Duijn CM; Mauser-Bunschoten EP; Eikenboom J; Leebeek FW;
J Thromb Haemost; 2015 Jun; 13(6):956-66. PubMed ID: 25832887
[TBL] [Abstract][Full Text] [Related]
5. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
[TBL] [Abstract][Full Text] [Related]
6. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD).
Tosetto A; Rodeghiero F; Castaman G; Bernardi M; Bertoncello K; Goodeve A; Federici AB; Batlle J; Meyer D; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Budde U; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill F; Peake I
J Thromb Haemost; 2007 Apr; 5(4):715-21. PubMed ID: 17408405
[TBL] [Abstract][Full Text] [Related]
7. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease.
Siboni SM; Biguzzi E; Caiani V; Mistretta C; Bucciarelli P; Peyvandi F
Haemophilia; 2016 Jul; 22(4):564-9. PubMed ID: 26843468
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of slightly reduced von Willebrand factor activity.
Bykowska K; Ceglarek B
Pol Arch Intern Med; 2020 Mar; 130(3):225-231. PubMed ID: 31990275
[TBL] [Abstract][Full Text] [Related]
10. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
Flood VH; Christopherson PA; Gill JC; Friedman KD; Haberichter SL; Bellissimo DB; Udani RA; Dasgupta M; Hoffmann RG; Ragni MV; Shapiro AD; Lusher JM; Lentz SR; Abshire TC; Leissinger C; Hoots WK; Manco-Johnson MJ; Gruppo RA; Boggio LN; Montgomery KT; Goodeve AC; James PD; Lillicrap D; Peake IR; Montgomery RR
Blood; 2016 May; 127(20):2481-8. PubMed ID: 26862110
[TBL] [Abstract][Full Text] [Related]
11. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).
Tosetto A; Rodeghiero F; Castaman G; Goodeve A; Federici AB; Batlle J; Meyer D; Fressinaud E; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Budde U; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill F; Peake I
J Thromb Haemost; 2006 Apr; 4(4):766-73. PubMed ID: 16634745
[TBL] [Abstract][Full Text] [Related]
12. The Association of Aging With Von Willebrand Factor Levels and Bleeding Risk in Type 1 Von Willebrand Disease.
Seaman CD; Ragni MV
Clin Appl Thromb Hemost; 2018 Apr; 24(3):434-438. PubMed ID: 28874064
[TBL] [Abstract][Full Text] [Related]
13. Effect of genetic variation in STXBP5 and STX2 on von Willebrand factor and bleeding phenotype in type 1 von Willebrand disease patients.
van Loon JE; Sanders YV; de Wee EM; Kruip MJ; de Maat MP; Leebeek FW
PLoS One; 2012; 7(7):e40624. PubMed ID: 22792389
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal bleeding assessment in von Willebrand disease utilizing an interim bleeding score.
Lavin M; Christopherson P; Grabell J; Abshire T; Flood V; Haberichter SL; Lillicrap D; O'Donnell JS; Montgomery RR; James PD
J Thromb Haemost; 2022 Oct; 20(10):2246-2254. PubMed ID: 35780487
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease.
Favaloro EJ
Thromb Haemost; 2010 Nov; 104(5):1009-21. PubMed ID: 20806123
[TBL] [Abstract][Full Text] [Related]
16. The necessity of repeat testing for von Willebrand disease in adult patients with mild to moderate bleeding disorders.
Mehic D; Kraemmer D; Tolios A; Bücheler J; Quehenberger P; Haslacher H; Ay C; Pabinger I; Gebhart J
J Thromb Haemost; 2024 Jan; 22(1):101-111. PubMed ID: 37741511
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand's disease: case report and review of literature.
Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
[TBL] [Abstract][Full Text] [Related]
18. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
[TBL] [Abstract][Full Text] [Related]
19. Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease.
Quiroga T; Goycoolea M; Belmont S; Panes O; Aranda E; Zúñiga P; Pereira J; Mezzano D
J Thromb Haemost; 2014 Aug; 12(8):1238-43. PubMed ID: 24796601
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]